Progressive decline in estimated glomerular filtration rate in patients with diabetes after moderate loss in kidney function-even without albuminuria
Open accessAbstract
OBJECTIVE: Persons with diabetes but no chronic kidney disease (CKD) and without albuminuria have the same age-related decline in kidney function as the background population. Whether this also applies following moderate loss in kidney function is unknown. We quantified the impact of albuminuria status on the development of estimated glomerular filtration rate (eGFR) trajectories following CKD stage 3 (CKD3) and assessed potential heterogeneous development patterns among the subgroup with normoalbuminuria. RESEARCH DESIGN AND METHODS: We used repeated clinical measures during up to 16 years of follow-up in 935 persons with type 1 diabetes and 1,984 with type 2 diabetes. Trajectories of eGFR by diabetes type and albuminuria status following CKD3 were estimated with spline mixed-effects models with adjustment for relevant confounders. Latent class trajectory modeling was used to find distinct patterns of eGFR development in the subgroups with normoalbuminuria. RESULTS: Mean annual declines in eGFR for normo-, micro- and macroalbuminuria the first 10 years following CKD3 were 1.9, 2.3, and 3.3 mL/min/1.73 m2 in type 1 diabetes and 1.9, 2.1, and 3.0 in type 2 diabetes, respectively. For normoalbuminuria, two distinct eGFR patterns were found, one with accelerated declining eGFR levels. This specific progression pattern was associated with less use of lipid-lowering treatment, renin-angiotensin system blockers, and other antihypertensive treatment. CONCLUSIONS: Our results support a diabetes-dependent decline in kidney function without albuminuria following CKD3, with a subgroup showing a progressive decline. Furthermore, this group seems to be undertreated in terms of cardioprotective and renal protective treatment and suggests that increased attention should be drawn to normoalbuminuric diabetic kidney disease.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Reduced eGFR without albuminuria has been frequently reported in type 1 and type 2 diabetes and is becoming more common over time as the prevalence of diabetes increases in the U.S.
“Reduced eGFR without albuminuria has been frequently reported in type 1 and type 2 diabetes and is becoming more common over time as the prevalence of diabetes increases in the U.S. (2,3,16,(19)(20)(21).”
From 11. Chronic Kidney Disease and Risk Management: Standards of Care in Diabetes—2025 (2025) · cites this paper as [21]
The Results report normoalbuminuria in participants with both type 1 and type 2 diabetes, and the Conclusions say that a substantial number enter CKD stage 3 without albuminuria and that this presentation is increasing, especially in type 2 diabetes. The paper does not establish that it is becoming more common in the U.S. or that rising U.S. diabetes prevalence is the reason. (LLM, conf=0.88)
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
The citation lists haven’t been fetched yet
References 38 · Cited by 167
- Authors
- Vistisen, D., Andersen, G. S., Hulman, A., Persson, F., Rossing, P., & Jørgensen, M. E.
- Affiliations
- Steno Diabetes Center Copenhagen (DK)
- Steno Diabetes Center Aarhus, Aarhus, Denmark
- University of Copenhagen (DK)
- University of Southern Denmark (DK)
- Corresponding author
- Vistisen, Dorte
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2019-06-20
- Volume
- 42
- Issue
- 10
- Pages
- 1886-1894
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- OpenAlex
- W2951812067
- Semantic Scholar
- 12eb365881614af40a3dda50bf1178a063af6ec6
- Cited by
- 167
- References
- 38
- Citations by year
- 2026: 14 · 2025: 20 · 2024: 25 · 2023: 22 · 2022: 24 · 2021: 36 · 2020: 22 · 2019: 4
- FWCI
- 16.58
- Type
- journal article
- Language
- en
- Open access
- Locations
- Diabetes Care (publishedVersion)
- PubMed (publishedVersion)
- Research at the University of Copenhagen (University of Copenhagen) (publishedVersion, cc-by)
- Scopus (Elsevier) (submittedVersion)
- University of Southern Denmark Research Portal (University of Southern Denmark) (submittedVersion)
- Funders
- Amgen
- Eli Lilly and Company
- AstraZeneca
- Sanofi
- Steno Diabetes Center Copenhagen (SDCC 3.A Complications, SDCC 3. B Epidemiology)
- Novo Nordisk
- Astellas Pharma
- Steno Diabetes Center Aarhus
- Topics
- Health Sciences › Medicine › Nephrology › Chronic Kidney Disease and Diabetes
- Health Sciences › Medicine › Nephrology › Acute Kidney Injury Research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Keywords
- estimated glomerular filtration rate decline, type 1 diabetes, type 2 diabetes, normoalbuminuria, diabetic nephropathy, chronic kidney disease stage 3, albuminuria, renin-angiotensin system inhibitors, lipid-lowering therapy, antihypertensive therapy
- MeSH terms
- Aged, Albuminuria, Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2, Diabetic Nephropathies, Female, Follow-Up Studies, Glomerular Filtration Rate, Humans, Male, Middle Aged, Disease Progression, Renal Insufficiency, Chronic
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review